脊柱关节炎17年再评估:诊断转变、生物制剂启用与死亡率
REGISPON-3研究对2004年REGISPONSER队列中536例脊柱关节炎患者于17年后进行再评估,411例完成现场评估、125例确认死亡。31.6%患者诊断发生变化,生物制剂使用率从13.1%升至52.1%,从症状出现至首次使用生物制剂的中位时间为32年(95%CI 30至35)。
要点
- 31.6%的患者在17年后诊断发生变化,主要为未分化脊柱关节炎转为中轴型脊柱关节炎或银屑病关节炎。
- 生物制剂使用率从13.1%升至52.1%,从症状出现至首次使用生物制剂的中位时间为32年。
- 125例死亡患者中,主要死因为感染(21.6%)、心血管事件(20.0%)和癌症(19.2%)。
核心结论
- 长期再评估显示脊柱关节炎患者存在显著的诊断变化,死亡负担主要归因于感染和心血管疾病。
研究设计与样本
- REGISPON-3为两时点纵向研究,纳入符合欧洲脊柱关节病研究组标准的REGISPONSER研究患者,于17年后重新评估。
- 2004年REGISPONSER研究的536例患者于2021年联系进行REGISPON-3访视,其中411例完成现场再评估,125例确认死亡。
- 收集临床、实验室、影像学和治疗数据并与基线比较,采用多因素logistic回归分析诊断变化相关因素,Kaplan-Meier生存分析评估生物制剂启用时间。
主要发现
- 411例再评估患者中31.6%发生诊断变化,主要为未分化脊柱关节炎转为中轴型脊柱关节炎或银屑病关节炎。
- 多因素分析中,指趾炎、较年轻年龄和较低Bath强直性脊柱炎放射学指数评分与诊断变化相关。
- 生物制剂使用率从13.1%升至52.1%。
- 从症状出现至首次使用生物制剂的中位时间为32年(95%CI 30至35),从诊断至首次使用的中位时间为28年(95%CI 26至32)。
- 125例死亡患者中,主要死因为感染(21.6%)、心血管事件(20.0%)和癌症(19.2%)。
关键数值与推荐
- 诊断变化率31.6%(411例再评估患者中)。
- 生物制剂使用率从13.1%升至52.1%。
- 从症状出现至首次生物制剂中位时间32年(95%CI 30至35),从诊断至首次生物制剂中位时间28年(95%CI 26至32)。
- 死亡患者主要死因:感染21.6%、心血管事件20.0%、癌症19.2%(125例死亡患者中)。
临床怎么用
- 长期随访中脊柱关节炎诊断可能发生转变,需关注从幼年未分化脊柱关节炎向中轴型脊柱关节炎或银屑病关节炎的演变。
- 指趾炎、较年轻年龄和较低放射学评分与诊断变化相关。
- 生物制剂启用延迟显著,从症状出现至首次使用中位时间达32年。
- 死亡负担主要来自感染和心血管疾病,提示长期管理中需关注这些合并症。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate disease evolution, diagnostic transitions, time to biologic treatment initiation and mortality in patients with spondyloarthritis (SpA) after 17 years from the original Spanish Registry of Spondyloarthritis (REGISPONSER). METHODS: Spondyloarthritis Registry 3 (REGISPON-3) is a two-timepoint longitudinal study with patients fulfilling the European Spondyloarthropathy Study Group criteria participating in the REGISPONSER study and re-evaluated after 17 years. Clinical, laboratory, radiological and treatment data were collected and compared with baseline. Diagnostic changes according to the rheumatologist's judgement and their associated factors were analysed using multivariable logistic regression. Time to initiation of biologic therapy was evaluated using Kaplan-Meier survival analysis. RESULTS: A total of 536 patients from the REGISPONSER study conducted in 2004 were contacted in 2021 for the REGISPON-3 visit. Of these, 411 were physically re-evaluated, while 125 were confirmed deceased. Among the 411 patients, 31.6% experienced a change in diagnosis in the REGISPON-3 visit, mainly from undifferentiated SpA to axial SpA or psoriatic arthritis. In multivariable analysis, dactylitis, younger age and lower Bath Ankylosing Spondylitis Radiology Index scores were associated with diagnostic change. The use of biologic disease-modifying antirheumatic drugs (bDMARDs) increased from 13.1% to 52.1%. However, the median time to first bDMARD from symptom onset was 32 years (95% CI 30 to 35) and 28 years from diagnosis (95% CI 26 to 32). Among the 125 patients who died, the leading causes were infections (21.6%), cardiovascular (CV) events (20.0%) and cancer (19.2%). CONCLUSIONS: This long-term reassessment reveals significant diagnostic changes in SpA and a mortality burden mainly attributed to infections and CV diseases.
引用
- Puche-Larrubia MÁ, Ladehesa-Pineda L, Ábalos-Aguilera MC, et al. Seventeen-year reassessment of diagnostic transitions, biologic therapy initiation and mortality in spondyloarthritis: results from the REGISPON-3 study. RMD Open. 2025. PMID: 41052888. doi:10.1136/rmdopen-2025-006031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。